Please switch to a supported browser to continue using this website.
Consider using the latest version of Google Chrome or Microsoft's Edge to view this website.
Please switch to a supported browser to continue using this website.
Consider using the latest version of Google Chrome or Microsoft's Edge to view this website.
Biotechnology leader CSL Behring offers the broadest range quality plasma-derived and recombinant therapies in our industry.
CSL Behring: Rare & Serious DiseasesDerived from the expression securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine companies.
CSL Seqirus: VaccinesR&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
R&D CapabilitiesOne of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
Awards, Grants and InitiativesAs part of our broader sustainability strategy to build a more sustainable future, we've commited to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Learn About Our TargetsAlong with our sustainability strategy, CSL's community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
Supporting Our CommunitiesAt CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Read About Our Approach to Inclusion and BelongingWhether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising fututre!
Early Careers at CSLOur exceptionally strong performance is a result of the focused execution of our strategy.
Learn moreBiotechnology leader CSL Behring offers the broadest range quality plasma-derived and recombinant therapies in our industry.
CSL Behring: Rare & Serious DiseasesDerived from the expression securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine companies.
CSL Seqirus: VaccinesR&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
R&D CapabilitiesOne of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
Awards, Grants and InitiativesAs part of our broader sustainability strategy to build a more sustainable future, we've commited to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Learn About Our TargetsAlong with our sustainability strategy, CSL's community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
Supporting Our CommunitiesAt CSL, Inclusion and Belonging is at the core of our mission and who we are. It fuels our innovation day in and day out.
Read About Our Approach to Inclusion and BelongingWhether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising fututre!
Early Careers at CSLOur exceptionally strong performance is a result of the focused execution of our strategy.
Learn moreWe have announced our 2026 Half Year Financial Results for the period ending 31st December 2025.
Announcement information was released on Wednesday, 11th February 2026 (AEDT).
Please click here to view the full Announcement Information.
Click here to view the Announcement Webcast.
CSL's 2025 AGM was held on Tuesday, 28th October 2025 (AEDT).
Learn More